Aviva
GCVRZ

Aviva’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Aviva’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-39,193
Closed -$76K – 853
2013
Q2 		$76K Buy
+39,193
New +$68.8K ﹤0.01% 832

Other funds holding GCVRZ

ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
DI
Dalton Investments Las Vegas, Nevada $103M AUM 3.77% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Aviva's GCVRZ Position: Q3 2013 in Review

Aviva sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2013, closing a stake of 39,193 shares — an estimated $76K sold.

Aviva first reported a position in GCVRZ in Q2 2013 and held it in 1 quarter. The position peaked at $76K in Q2 2013. 136 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2013.

  • Aviva reported no remaining Sanofi Contingent Value Rights position as of Q3 2013 after selling out during the quarter.
  • Aviva sold 39,193 Sanofi Contingent Value Rights shares in Q3 2013, an estimated $76K.
  • Aviva first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 1 quarter.
  • Aviva's Sanofi Contingent Value Rights position peaked at $76K in Q2 2013.
  • 136 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2013.

Based on Aviva's 13F filing for Q3 2013, filed 13 Nov 2013.